CoronaVIR

CoronaVIR consolidates and maintains a repository of predicted and existing information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to support genomic analysis, diagnostic primer prediction, immunotherapy candidate identification, and drug-design research.

Key Features:

• Genomics Module: Provides detailed genomic information on different SARS-CoV-2 strains and facilitates analysis of genomic alterations.
• Diagnosis Module: Includes data on currently utilized diagnostic tests and five novel universal primer sets predicted using in silico tools.
• Immunotherapy Module: Presents epitope-based potential vaccine candidates (LQLPQGTTLPKGFYA, VILLNKHIDAYKTFPPTEPKKDKKKK, EITVATSRTLS, GKGQQQQGQTV, SELVIGAVILR) predicted to activate adaptive (B cell and T cell) and innate immune responses including vaccine adjuvants, and explores siRNA-based therapies and RNA-based vaccine adjuvants suitable for all SARS-CoV-2 strains.
• Drug Designing Module: Maintains a database of potential drug targets, tertiary structures, and candidate molecules identified through docking-based approaches using FDA-approved drugs, and compiles literature and internet-sourced data on potential drugs, repurposing strategies, monoclonal antibodies, host–virus interactions, and cell-penetrating peptides.

Scientific Applications:

• Genomic research: Enables investigation of viral evolution and mutation patterns across SARS-CoV-2 strains.
• Diagnostic development: Supports design and evaluation of diagnostic assays through primer predictions and diagnostic-test data.
• Vaccine design: Facilitates identification of epitope-based vaccine candidates and evaluation of immune adjuvant strategies.
• Therapeutic discovery: Supports repurposing and discovery of therapeutic candidates via docking-based screening and compilation of drug-related data.

Methodology:

Computational methods explicitly include in silico primer prediction; epitope prediction/immune informatics for B cell and T cell epitopes and vaccine adjuvants; exploration of siRNA-based therapies and RNA-based vaccine adjuvants; docking-based screening of FDA-approved drugs against tertiary structures; and compilation of literature and internet-sourced data.